Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) (ARDIS-1)
|Irritable Bowel Syndrome With Diarrhea||Drug: Rezular 15mg Drug: Placebo Drug: Rezular||Phase 3|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||A Randomized, Double-Blind, Placebo-Controlled Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)|
- Adequate Relief [ Time Frame: 8 weeks ]
|Study Start Date:||September 2007|
|Study Completion Date:||June 2009|
|Primary Completion Date:||June 2009 (Final data collection date for primary outcome measure)|
|Placebo Comparator: 1||
Drug: Rezular 15mg
|Experimental: Rezular 37.5mg||
Rezular 37.5mg 3xday up to 12 weeks
|Experimental: Rezular - 75mg||
Rezular 75mg 3xday up to 12 weeks
We have fulfilled our enrollment requirements for this study.
This study has been designed as a multicenter, randomized, double-blind, placebo controlled parallel dose group trial. The study will be open to both women and men. At screening the patient will be assessed to see if they meet the Rome III criteria for IBS-D. After screening, patients will undergo a 14-day run-in period evaluation, during which eligibility to be randomized to drug or placebo will be determined. Patients will complete daily telephone diaries during the run-in and double-blind phases of the study. Patients will be evaluated at regularly scheduled clinic visits during double-blind phase of the study.
Patients who complete the study may have the opportunity to rollover to the open-label one-year safety study (ARDIS-3).
Please refer to this study by its ClinicalTrials.gov identifier: NCT00552565
|United States, North Carolina|
|Wilmington, North Carolina, United States, 28401|